	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	193.35	357.09	461.33	463.54	505.05	703.06
Cost of Operating Revenue	180.04	338.77	431.85	423.72	441.98	623.17
Gross Profit	13.31	18.32	29.48	39.82	63.07	79.89
Gross Margin	6.9	5.1	6.4	8.6	12.5	11.4
Total Operating Expenses	186.93	346.89	447.31	441.97	467.35	655.53
Operating Profit	6.42	10.20	14.02	21.57	37.70	47.53
Operating Margin	3.3	2.9	3.0	4.7	7.5	6.8
Financing Income/(Expense) - Net	-3.23	-3.38	-5.40	-8.94	-15.77	-25.70
Profit before Taxes	3.57	7.19	9.50	15.23	21.63	30.54
Income Taxes	0.90	1.89	2.46	3.77	5.68	7.17
Profit after Tax	2.67	5.30	7.04	11.46	15.95	23.30
PAT Margin	1.4	1.5	1.5	2.5	3.2	3.3
EPS - Basic - ex Extraordinary Items	0.27	0.54	0.55	0.48	0.66	0.97
EPS - Diluted - ex Extraordinary Items	0.27	0.54	0.55	0.48	0.66	0.97
EBIT	6.42	10.20	14.02	21.57	37.70	47.53
EBITDA	7.16	11.07	14.93	22.81	39.92	51.32
EBITDA Margin	3.7	3.1	3.2	4.9	7.9	7.3

Balance Sheet

Abridged

Understanding Balance Sheet

Sudarshan Pharma Industries Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	PRESS
Total Current Assets	87.64	129.58	198.62	241.57	334.85	490.26
Long-Term Investments	0.00	0.00	12.34	12.34	28.84	42.91
Property Plant & Equipment - Net	5.98	6.88	19.00	22.41	26.09	80.85
Total Non-Current Assets	11.62	7.94	33.86	41.55	67.56	151.48
Total Assets	99.26	137.52	232.48	283.13	402.41	641.75
Total Current Liabilities	71.22	101.04	118.48	160.82	259.69	456.12
Long Term Debt	5.32	6.52	12.79	10.49	10.46	28.63
Total Non-Current Liabilities	5.48	6.71	13.03	10.59	11.23	29.31
Total Liabilities	76.70	107.75	131.50	171.42	270.93	485.43
Total Shareholders' Equity	22.51	29.78	100.97	111.71	131.48	155.10
Minority Interest	0.05	-	-	-	0.00	1.22
Total Equity	22.56	29.78	100.97	111.71	131.48	156.32
Total Liabilities & Equity	99.26	137.52	232.48	283.13	402.41	641.75

Cash Flow

Abridged

Understanding Cash Flow Statement

Sudarshan Pharma Industries Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	4.32	8.06	10.40	16.47	26.91	31.77
Working Capital - Increase/(Decrease)	-12.30	-14.62	-39.77	-87.02	-72.34	-57.30
Net CF from Operating Activities	-7.99	-6.57	-29.37	-70.55	-45.43	-25.53
Capital Expenditures - Net	1.32	1.66	13.80	3.78	4.75	47.09
Net CF from Investing Activities	-1.32	-1.66	-26.14	-6.28	-21.21	-79.12
Dividends Paid - Cash - Total	-	-	-	0.72	-	-
Stock - Issuance/(Retirement) - Net	-	2.02	64.16	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	9.24	5.29	2.83	65.97	63.18	103.83
Net Cash Flow from Financing Activities	9.29	7.20	66.99	65.25	67.00	103.83
Free Cash Flow to Equity	-0.06	-2.93	-40.34	-8.36	13.01	31.21
Free Operating CF net dividend	-9.31	-8.22	-43.70	-75.05	-50.17	-94.63
Free Operating CF	-9.31	-8.22	-43.70	-74.33	-50.17	-94.63

Business Segment Analysis

FY End:

Mar 23

Sudarshan Pharma Industries Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Sudreshan Pharma Industries Ltd (100.0%)₹ 14.33 Cr

Revenue / Sales

Sudreshan Pharma Industries Ltd (100.0%)₹ 461.33 Cr

Assets

Sudreshan Pharma Industries Ltd (100.0%)₹ 232.48 Cr

Operating Income

Sudreshan Pharma Industries Ltd (100.0%)₹ 14.02 Cr

Regional Segment Analysis

FY End:

Mar 23

Sudarshan Pharma Industries Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (100.0%)₹ 461.33 Cr

Assets

India (100.0%)₹ 232.48 Cr

Historical Segment Analysis

Track how Sudarshan Pharma Industries Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31

Sudreshan Pharma Industries Ltd	14

Frequently Asked Questions

What is the revenue of Sudarshan Pharma Industries Ltd.?

The latest trailing twelve month revenue of Sudarshan Pharma Industries Ltd. is ₹ 703.06 Cr, reflecting a 1-year growth of 39.21% and a 3-year CAGR of 15.08%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sudarshan Pharma Industries Ltd.?

The latest trailing twelve month net profit (PAT) of Sudarshan Pharma Industries Ltd. is ₹ 23.30 Cr, with a 3-year earnings CAGR of 21.00%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sudarshan Pharma Industries Ltd.?

The trailing twelve month EBITDA of Sudarshan Pharma Industries Ltd. is approximately ₹ 47.53 Cr (based on an operating margin of 6.76%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sudarshan Pharma Industries Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sudarshan Pharma Industries Ltd. is 0.97. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sudarshan Pharma Industries Ltd.?

The debt-to-equity ratio of Sudarshan Pharma Industries Ltd. stands at 1.84. The interest coverage ratio is 1.85x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sudarshan Pharma Industries Ltd.?

The estimated book value per share of Sudarshan Pharma Industries Ltd. is 6.21 (derived from a P/B ratio of 6.57 and market price of ₹ 40.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sudarshan Pharma Industries Ltd.?

The trailing twelve month operating cash flow of Sudarshan Pharma Industries Ltd. is ₹ -25.53 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sudarshan Pharma Industries Ltd. report consolidated or standalone financials?

Sudarshan Pharma Industries Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.